Luke Timmerman


EQRx Taps Zeitgeist, Raises $200m For Innovative Drugs at Aggressive Low Prices

Alexis Borisy is smart. As in high IQ. But there’s more to biopharma than that. “As my grandmother used to say, ‘You can be smart, smart, smart…but dumb,’” Borisy said. Some old wisdom is part of what’s driving Cambridge, Mass.-based EQRx. The company, started by the former Third Rock Ventures partner and backed by $200 million of “smart money” in...
Read More

Designer Proteins as Better Therapies: David Baker on The Long Run

Today’s guest on The Long Run is David Baker. David is a biochemistry professor at the University of Washington, a Howard Hughes Medical Institute investigator, and the director of The Institute for Protein Design at the University of Washington. Just like the name suggests, this institute works on designing proteins with special properties. Sometimes these proteins are designed on computers,...
Read More

Turning Synthetic Biology Into ‘Living Drugs’: Synlogic’s Aoife Brennan on The Long Run

Today’s guest on The Long Run is Aoife Brennan. Aoife (it’s pronounced EE-fuh in her native Ireland) is the CEO of Synlogic Therapeutics. The company, based in Cambridge, Mass., is trying to build on years of work at MIT in synthetic biology. The basic idea is to create what the company calls Synthetic Biotics, or what you can call “Living...
Read More
1 2 3 26